Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?

Clin Microbiol Infect. 2023 Aug;29(8):1093-1095. doi: 10.1016/j.cmi.2023.05.010. Epub 2023 May 13.

¹ Microbiology Service, Hospital Clínico Universitario, Institto De Investigación Sanitaria (INCLIVA Health Research Institute), Valencia, Spain.
² Hematology Service, Hospital Clínico Universitario, Institto De Investigación Sanitaria (INCLIVA Health Research Institute), Valencia, Spain.
³ Microbiology Service, Hospital Universitario y Politécnico "La Fe", Valencia, Spain.
⁴ Microbiology Service, Hospital Clínico Universitario, Institto De Investigación Sanitaria (INCLIVA Health Research Institute), Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
⁵ Hematology Service, Hospital Clínico Universitario, Institto De Investigación Sanitaria (INCLIVA Health Research Institute), Valencia, Spain; Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
⁶ Hematology Service, Hospital Universitario y Politécnico "La Fe", Valencia, Spain.
⁷ Microbiology Service, Hospital Clínico Universitario, Institto De Investigación Sanitaria (INCLIVA Health Research Institute), Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain. Electronic address: david.navarro@uv.es.

No abstract available

Keywords: B-cell lymphoma; CD19 CAR T-cell therapy; CMV DNAemia; CMV end-organ disease; Cytomegalovirus (CMV).

Publication types